Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Xilio Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 36 | 1 | 37 | +2 |
| Shares | 22.1M | 1.48M | 39.7M | +19.2M (+93.1%) |
| Value | $18.6M | $1.24M | $25.4M | +$8.06M (+46.4%) |
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Xilio Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5,915,091 | $3.79M | 0.10% |
| Point72 Asset Management, L.P. | 4,000,000 | $2.56M | 0.00% |
| Sio Capital Management, LLC | 2,134,537 | $1.37M | 0.23% |
| StemPoint Capital LP | 2,030,028 | $1.30M | 0.22% |
| Empery Asset Management, LP | 1,183,040 | $757.4K | 0.67% |
| Ghisallo Capital Management LLC | 1,113,222 | $712.7K | 0.03% |
| Citadel Advisors LLC | 436,216 | $279.3K | 0.00% |
| Velan Capital Investment Management LP | 170,000 | $108.8K | 0.06% |
| Gsa Capital Partners LLP | 147,966 | $95.0K | 0.01% |
| Stonepine Capital Management, LLC | 126,270 | $80.8K | 0.06% |
| Jane Street Group, LLC | 42,080 | $26.9K | 0.00% |
Sold out (9)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Squarepoint Ops LLC | 328,794 | $277.1K |
| Trustees of Columbia University in the City of New York | 249,635 | $210.4K |
| Balyasny Asset Management LLC | 198,859 | $167.6K |
| Two Sigma Securities, LLC | 32,130 | $27.1K |
| Two Sigma Advisers, LP | 29,689 | $25.0K |
| Aptus Capital Advisors, LLC | 25,000 | $21.1K |
| SevenBridge Financial Group, LLC | 25,000 | $19.3K |
| Federation des caisses Desjardins du Quebec | 3,300 | $2.78K |
| Citigroup Inc | 258 | $217 |
Not filed for Q4 2025 yet (1)
Institutions that held Xilio Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Takeda Pharmaceutical Co Ltd | 1,475,121 | $1.24M |